Top Highlights From the 2016 ASCO GU Cancers Symposium

Slideshow
Conference|ASCO Gastrointestinal Cancer Symposium

This slide show includes some of the top highlights from the 2016 ASCO Genitourinary Cancers Symposium, including studies on hypofractionation in low-risk prostate cancer, cabozantinib in advanced RCC, and more.

References:

1. Lee WR, Dignam JJ, Amin M, et al. NRG Oncology RTOG 0415: A randomized phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer. Presented at the 2016 Genitourinary Cancers Symposium. Abstract 1.

2. Dearnaley DP, Syndikus I, Mossop H, et al. Comparison of hypofractionated high-dose intensity-modulated radiotherapy schedules for prostate cancer: Results from the phase III randomized CHHiP trial (CRUK/06/016). Presented at the 2016 Genitourinary Cancers Symposium. Abstract 2.

3. Shipley WU, Pugh SL, Lukka HR, et al. NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA. Presented at the 2016 Genitourinary Cancers Symposium. Abstract 3.

4. Scher HI, Graf R, Louw J, et al. Single CTC characterization to identify phenotypic and genomic heterogeneity as a mechanism of resistance to AR signaling directed therapies (AR Tx) in mCRPC patients. Presented at the 2016 Genitourinary Cancers Symposium. Abstract 163.

5. Abel EJ, Zargar K, Margulis V, et al. Role of cytoreductive nephrectomy in renal cell cancer (RCC) with venous tumor thrombus. Presented at the 2016 Genitourinary Cancers Symposium. Abstract 496.

6. Motzer RJ, Sharma P, McDermott DF, et al. CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).  Presented at the 2016 Genitourinary Cancers Symposium. Abstract 498.

7. Escudier BJ, Motzer RJ, Powles T, et al. Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC). Presented at the 2016 Genitourinary Cancers Symposium. Abstract 499.

Recent Videos
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Related Content
Investigators from the United States, United Kingdom, Canada, and Germany look to conduct a primary prevention trial in patients with Li-Fraumeni syndrome.

Forming International Collaborative Efforts to Assess Metformin Use in LFS

Russ Conroy
October 24th 2024
Article

Investigators from the United States, United Kingdom, Canada, and Germany look to conduct a primary prevention trial in patients with Li-Fraumeni syndrome.

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Exploring New Possibilities in Kidney Cancer Detection and Therapy

Karl Semaan, MD, MSc ;Neil J. Shah, MBBS;Bradley McGregor, MD
July 22nd 2024
Podcast

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Bin Gui, MD, discussed how ultra-hypofractionated radiotherapy may be a convenient treatment option for elderly patients with early breast cancer.

Ultra-Hypofractionated RT Shows Control, Tolerability in Elderly Breast Cancer

Russ Conroy
October 17th 2024
Article

Bin Gui, MD, discussed how ultra-hypofractionated radiotherapy may be a convenient treatment option for elderly patients with early breast cancer.

Experts discuss updated findings presented at the 2024 EHA Congress in diseases such as mantle cell lymphoma and acute myeloid leukemia.

Ensuring Quality Outcomes in Hematologic Cancer Subgroups at EHA 2024

Manali Kamdar, MD;Michael Grunwald, MD;Harry P. Erba, MD, PhD
June 24th 2024
Podcast

Experts discuss updated findings presented at the 2024 EHA Congress in diseases such as mantle cell lymphoma and acute myeloid leukemia.

Data from the ARANOTE trial may support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC.

Darolutamide/ADT Improves rPFS in Metastatic HSPC

Jonah Feldman
October 13th 2024
Article

Data from the ARANOTE trial may support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC.

P-BCMA-ALLO1 yielded lymphodepletion responses even among those with prior exposure to other CAR T-cell therapies or bispecific agents.

Novel Allogenic CAR T Therapy Shows Responses in R/R Multiple Myeloma

Courtney Flaherty
October 12th 2024
Article

P-BCMA-ALLO1 yielded lymphodepletion responses even among those with prior exposure to other CAR T-cell therapies or bispecific agents.